Carroll Financial Associates’s Halozyme HALO Stock Holding History

Carroll Financial Associates’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,000	Closed	-$12K	–	1213
2017 Q2	$12K	Hold	1,000	–	–	﹤0.01%	793
2017 Q1	$12K	Hold	1,000	–	–	﹤0.01%	784
2016 Q4	$9K	Hold	1,000	–	–	﹤0.01%	815
2016 Q3	$12K	Hold	1,000	–	–	﹤0.01%	772
2016 Q2	$8K	Hold	1,000	–	–	﹤0.01%	834
2016 Q1	$9K	Hold	1,000	–	–	﹤0.01%	786
2015 Q4	$17K	Hold	1,000	–	–	﹤0.01%	622
2015 Q3	$13K	Hold	1,000	–	–	﹤0.01%	662
2015 Q2	$23K	Buy	+1,000	New	+$17.6K	0.01%	526
2014 Q4	–	Sell	-1,000	Closed	-$8K	–	778
2014 Q3	$8K	Hold	1,000	–	–	﹤0.01%	596
2014 Q2	$10K	Hold	1,000	–	–	﹤0.01%	601
2014 Q1	$13K	Hold	1,000	–	–	﹤0.01%	484
2013 Q4	$14K	Hold	1,000	–	–	0.01%	466
2013 Q3	$11K	Hold	1,000	–	–	﹤0.01%	507
2013 Q2	$7K	Buy	+1,000	New	+$6.37K	﹤0.01%	462

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carroll Financial Associates's HALO Position: Q3 2017 in Review

Carroll Financial Associates sold out of Halozyme (HALO) in Q3 2017, closing a stake of 1,000 shares — an estimated $12K sold.

Carroll Financial Associates first reported a position in HALO in Q2 2013 and held it in 15 quarters. The position peaked at $23K in Q2 2015. 166 funds tracked by Wall St. Rank hold HALO as of Q3 2017.

Carroll Financial Associates reported no remaining Halozyme position as of Q3 2017 after selling out during the quarter.
Carroll Financial Associates sold 1,000 Halozyme shares in Q3 2017, an estimated $12K.
Carroll Financial Associates first reported a position in Halozyme in Q2 2013 and held it in 15 quarters.
Carroll Financial Associates's Halozyme position peaked at $23K in Q2 2015.
166 funds tracked by Wall St. Rank held Halozyme as of Q3 2017.

Based on Carroll Financial Associates's 13F filing for Q3 2017, filed 25 Oct 2017.